We're developing a broad portfolio that has the potential to meaningfully improve millions of lives.
Program (Target)
Indication(s)
Stage of Development
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
NEURODEGENERATION
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
UB-311
(Aβ)
Alzheimer’s
UB-312
(α-synuclein)
Parkinson’s, DLB, MSA
VXX-301
(tau)
Alzheimer’s, Other
NEXT WAVE
CHRONIC
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
UB-313
(CGRP)
Migraine
VXX-401
(PCSK9)
Hypercholesterolemia
INFECTIOUS
DISEASE
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
UB-612
(SARS-CoV-2)
COVID-19
Clinical Trials
Vaxxinity is committed to developing safe and effective immunotherapeutic vaccines, with a goal of providing our next generation products as soon as possible through efficient product development. At this time, Vaxxinity’s investigational products can only be accessed through participation in a clinical trial. For detailed information on our ongoing clinical trials, please CLICK HERE. Vaxxinity does not currently offer an expanded access program.